LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Radicicol | 0.04 | uM | LJP6 | 72 | hr | 868 | 3982 | 3486 | 1.1422 | 1.1893 |
MDA-MB-231 | Seliciclib | 0.04 | uM | LJP5 | 72 | hr | 868 | 3636 | 3486 | 1.0430 | 1.0573 |
MDA-MB-231 | Ruxolitinib | 0.04 | uM | LJP5 | 72 | hr | 868 | 3160 | 3486 | 0.9066 | 0.8756 |
MDA-MB-231 | XL147 | 0.04 | uM | LJP5 | 72 | hr | 868 | 3749 | 3486 | 1.0754 | 1.1004 |
MDA-MB-231 | Saracatinib | 0.04 | uM | LJP6 | 72 | hr | 868 | 3338 | 3486 | 0.9575 | 0.9435 |
MDA-MB-231 | Selumetinib | 0.04 | uM | LJP6 | 72 | hr | 868 | 3237 | 3486 | 0.9287 | 0.9050 |
MDA-MB-231 | Sirolimus | 0.04 | uM | LJP6 | 72 | hr | 868 | 2868 | 3486 | 0.8228 | 0.7641 |
MDA-MB-231 | Sorafenib | 0.04 | uM | LJP6 | 72 | hr | 868 | 3447 | 3486 | 0.9889 | 0.9852 |
MDA-MB-231 | SU11274 | 0.04 | uM | LJP5 | 72 | hr | 868 | 3885 | 3486 | 1.1144 | 1.1524 |
MDA-MB-231 | Fedratinib | 0.04 | uM | LJP5 | 72 | hr | 868 | 3697 | 3486 | 1.0604 | 1.0804 |
MDA-MB-231 | TGX221 | 0.04 | uM | LJP5 | 72 | hr | 868 | 2426 | 3486 | 0.6960 | 0.5953 |
MDA-MB-231 | Torin1 | 0.04 | uM | LJP6 | 72 | hr | 868 | 1971 | 3486 | 0.5655 | 0.4215 |
MDA-MB-231 | Torin2 | 0.04 | uM | LJP5 | 72 | hr | 868 | 1312 | 3486 | 0.3765 | 0.1698 |
MDA-MB-231 | Tozasertib | 0.04 | uM | LJP5 | 72 | hr | 868 | 1053 | 3486 | 0.3021 | 0.0707 |
MDA-MB-231 | Trametinib | 0.04 | uM | LJP5 | 72 | hr | 868 | 1088 | 3486 | 0.3122 | 0.0841 |
MDA-MB-231 | TWS119 | 0.04 | uM | LJP5 | 72 | hr | 868 | 3371 | 3486 | 0.9669 | 0.9559 |
MDA-MB-231 | Vemurafenib | 0.04 | uM | LJP5 | 72 | hr | 868 | 3240 | 3486 | 0.9295 | 0.9062 |
MDA-MB-231 | Withaferin A | 0.04 | uM | LJP5 | 72 | hr | 868 | 3875 | 3486 | 1.1116 | 1.1485 |
MDA-MB-231 | Withaferin A | 0.04 | uM | LJP6 | 72 | hr | 868 | 3607 | 3486 | 1.0347 | 1.0462 |
MDA-MB-231 | WYE-125132 | 0.04 | uM | LJP6 | 72 | hr | 868 | 2273 | 3486 | 0.6522 | 0.5368 |
MDA-MB-231 | WZ3105 | 0.04 | uM | LJP5 | 72 | hr | 868 | 682 | 3486 | 0.1957 | -0.0710 |
MDA-MB-231 | XMD11-50 | 0.04 | uM | LJP6 | 72 | hr | 868 | 3077 | 3486 | 0.8828 | 0.8439 |
MDA-MB-231 | Y39983 | 0.04 | uM | LJP6 | 72 | hr | 868 | 3238 | 3486 | 0.9288 | 0.9051 |
MDA-MB-231 | YM 201636 | 0.04 | uM | LJP5 | 72 | hr | 868 | 3606 | 3486 | 1.0344 | 1.0458 |
MDA-MB-231 | ZSTK474 | 0.04 | uM | LJP6 | 72 | hr | 868 | 3338 | 3486 | 0.9574 | 0.9433 |